Page 130 - 《中国药房》2025年17期

[19] TVEIT K M，GUREN T，GLIMELIUS B，et al. Phase Ⅲ as first-line chemotherapy in metastatic colorectal cancer
trial of cetuximab with continuous or intermittent fluorou- [J]. Clin Cancer Res，2019，25（10）：2988-2995.
racil，leucovorin，and oxaliplatin（Nordic FLOX） versus [29] QIN S K，LI J，WANG L W，et al. Efficacy and tolerabi-
FLOX alone in first-line treatment of metastatic colorectal lity of first-line cetuximab plus leucovorin，fluorouracil，
cancer：the NORDIC-Ⅶ study[J]. J Clin Oncol，2012，30 and oxaliplatin（FOLFOX-4） versus FOLFOX-4 in pa‐
（15）：1755-1762. tients with RAS wild-type metastatic colorectal cancer：
[20] VAN CUTSEM E，KÖHNE C H，LÁNG I，et al. Cetu- the open-label，randomized，phase Ⅲ TAILOR trial[J]. J
ximab plus irinotecan，fluorouracil，and leucovorin as first- Clin Oncol，2018，36（30）：3031-3039.
line treatment for metastatic colorectal cancer：updated [30] ROSSINI D，ANTONIOTTI C，LONARDI S，et al. Up‐
analysis of overall survival according to tumor KRAS and front modified fluorouracil，leucovorin，oxaliplatin，and
BRAF mutation status[J]. J Clin Oncol，2011，29（15）： irinotecan plus panitumumab versus fluorouracil，leucovo‐
2011-2019. rin，and oxaliplatin plus panitumumab for patients with
[21] ANTONIOTTI C，BORELLI B，ROSSINI D，et al. Atezo‐ RAS/BRAF wild-type metastatic colorectal cancer：the
TRIBE：a randomised phase Ⅱ study of FOLFOXIRI plus phase Ⅲ TRIPLETE study by GONO[J]. J Clin Oncol，
bevacizumab alone or in combination with atezolizumab 2022，40（25）：2878-2888.
as initial therapy for patients with unresectable metastatic [31] SCHMOLL H J，MANN J，MEINERT F，et al. Efficacy
colorectal cancer[J]. BMC Cancer，2020，20（1）：683. and quality of life for FOLFOX/bevacizumab +/－ irinote‐
[22] ARANDA E，VIÉITEZ J M，GÓMEZ-ESPAÑA A，et al. can in first-line metastatic colorectal cancer-final results
FOLFOXIRI plus bevacizumab versus FOLFOX plus be‐ of the AIO CHARTA trial[J]. Br J Cancer，2024，130（2）：
vacizumab for patients with metastatic colorectal cancer 233-241.
and ≥3 circulating tumour cells：the randomised phase Ⅲ [32] SHIOZAWA M，SUNAKAWA Y，WATANABE T，et al.
VISNÚ-1 trial[J]. ESMO Open，2020，5（6）：e000944. Modified FOLFOXIRI plus cetuximab versus bevaci‐
[23] HEINEMANN V，VON WEIKERSTHAL L F，DECKER zumab in RAS wild-type metastatic colorectal cancer：a
T，et al. FOLFIRI plus cetuximab or bevacizumab for ad‐ randomized phase Ⅱ DEEPER trial[J]. Nat Commun，
vanced colorectal cancer：final survival and per-protocol 2024，15（1）：10217.
analysis of FIRE-3，a randomised clinical trial[J]. Br J [33] STINTZING S，HEINRICH K，TOUGERON D，et al.
Cancer，2021，124（3）：587-594. FOLFOXIRI plus cetuximab or bevacizumab as first-line
[24] LENZ H J，PARIKH A，SPIGEL D R，et al. Modified treatment of BRAF（V600E）-mutant metastatic colorectal
FOLFOX6 plus bevacizumab with and without nivolumab cancer：the randomized phase Ⅱ FIRE-4.5（AIO KRK0116）
for first-line treatment of metastatic colorectal cancer： study[J]. J Clin Oncol，2023，41（25）：4143-4153.
phase 2 results from the CheckMate 9X8 randomized clini- [34] TANG W T，REN L，LIU T S，et al. Bevacizumab plus
cal trial[J]. J Immunother Cancer，2024，12（3）：e008409. mFOLFOX6 versus mFOLFOX6 alone as first-line treat‐
[25] MAIELLO E，DI MAGGIO G，CORDIO S，et al. Bevaci‐ ment for RAS mutant unresectable colorectal liver-limited
zumab in combination with either FOLFOX-4 or XELOX- metastases：the BECOME randomized controlled trial[J]. J
2 in first-line treatment of patients with metastatic colorec‐ Clin Oncol，2020，38（27）：3175-3184.
tal cancer：a multicenter randomized phase Ⅱ trial of the [35] LU H J，LIN J K，CHEN W S，et al. Primary tumor loca‐
Gruppo Oncologico dell’Italia Meridionale（GOIM 2802） tion is an important predictive factor for wild-type KRAS
[J]. Clin Colorectal Cancer，2020，19（2）：109-115. metastatic colon cancer treated with cetuximab as front-
[26] MODEST D P，MARTENS U M，RIERA-KNORRENSCHILD line bio-therapy[J]. Asia Pac J Clin Oncol，2016，12（3）：
J，et al. FOLFOXIRI plus panitumumab as first-line treat‐ 207-215.
ment of RAS wild-type metastatic colorectal cancer：the [36] THIBAUDIN M，FUMET J D，CHIBAUDEL B，et al.
randomized，open-label，phase Ⅱ VOLFI study（AIO First-line durvalumab and tremelimumab with chemo‐
KRK0109）[J]. J Clin Oncol，2019，37（35）：3401-3411. therapy in RAS-mutated metastatic colorectal cancer：a
[27] OKI E，EMI Y，YAMANAKA T，et al. Randomised phase phase 1b/2 trial[J]. Nat Med，2023，29（8）：2087-2098.
Ⅱ trial of mFOLFOX6 plus bevacizumab versus [37] DEPAUW L，TOWNSEND A，KARAPETIS C，et al.
mFOLFOX6 plus cetuximab as first-line treatment for Role of locoregional therapy including liver transplanta‐
colorectal liver metastasis（ATOM trial）[J]. Br J Cancer， tion in liver-only metastatic colorectal cancer：a review pa‐
2019，121（3）：222-229. per[J]. Expert Rev Anticancer Ther，2025，25（1）：41-53.
[28] PARIKH A R，LEE F C，YAU L，et al. MAVERICC，a （收稿日期：2025-03-14 修回日期：2025-07-30）
randomized，biomarker-stratified，phase Ⅱ study of （编辑：刘明伟）
mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab

· 2204 · China Pharmacy 2025 Vol. 36 No. 17 中国药房 2025年第36卷第17期